Gemtuzumab Ozogamicin provides a CD33-targeting antibody-drug conjugate (ADC) for leukemia and oncology research. Also known as Mylotarg, it combines a CD33-directed monoclonal antibody with a calicheamicin-derived DNA-damaging payload and specifically supports studies of targeted cytotoxicity, acute myeloid leukemia (AML), and antibody-mediated drug delivery.
Key Features and Benefits
- CD33-Targeting ADC: Combines a CD33-directed monoclonal antibody with a potent calicheamicin-derived cytotoxic payload.
- Calicheamicin Payload: Contains an N-acetyl gamma calicheamicin derivative that induces DNA damage and supports investigation of ADC-mediated cytotoxicity.
- CD33 Recognition: Supports investigation of CD33 expression, antibody binding, internalization, and leukemia cell targeting.
- Cleavable Linker: Uses an acid-labile hydrazone-containing linker that specifically facilitates intracellular payload release following cellular uptake.
- Targeted Payload Delivery: Supports investigation of antibody-mediated delivery of calicheamicin derivatives to CD33-expressing cells.
- DNA Damage Mechanism: The released payload induces DNA strand breaks, specifically supporting studies of DNA damage responses and apoptosis.
- Myeloid Cell Targeting: Enables investigation of CD33 expression and ADC activity in myeloid leukemia cell models.
- Established ADC Platform: Provides a clinically established ADC for studying CD33-directed targeting and DNA-damaging payload activity.
Applications
- Acute Myeloid Leukemia Research: Supports investigation of CD33-targeted ADC mechanisms in AML cell models.
- CD33-Positive Leukemia Research: Especially useful for studying antibody targeting and cytotoxic responses in CD33-expressing leukemia cells.
- Myeloid Malignancy Research: Supports investigation of CD33 expression and targeted cytotoxicity in relevant myeloid cancer models.
- ADC Research: Useful for studying antibody binding, internalization, intracellular processing, and payload release.
- DNA Damage Research: Supports investigation of calicheamicin-mediated DNA strand breaks and associated cellular responses.
- Targeted Cancer Research: Enables studies of antibody-mediated delivery of potent DNA-damaging agents to leukemia cells.
- Cell-Based Leukemia Assays: Useful for evaluating CD33-dependent binding, cellular uptake, cytotoxicity, and apoptosis.
- Mechanism-of-Action Studies: Supports investigation of CD33 targeting, calicheamicin activity, and DNA damage-induced cell death.
- Comparative ADC Research: Useful for comparing CD33-directed ADCs, linker systems, and DNA-damaging payloads.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures specifically for antibody-drug conjugates and highly potent cytotoxic research materials. Maintain conditions that preserve antibody and conjugate stability.
Gemtuzumab Ozogamicin combines CD33-directed antibody targeting with a calicheamicin-derived DNA-damaging payload and specifically supports acute myeloid leukemia, CD33-positive leukemia, ADC, DNA damage, and targeted drug delivery research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
